Cargando…

A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation

BACKGROUND: Patients with hepatocellular carcinoma waiting for liver transplantation are commonly treated with locoregional treatments, such as TACE and ablation, to prevent tumor progression and dropout and to improve long-term outcome after transplantation. We wanted to prospectively assess feasib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eilard, Malin Sternby, Andersson, Mats, Naredi, Peter, Geronymakis, Charalampos, Lindnér, Per, Cahlin, Christian, Bennet, William, Rizell, Magnus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560824/ https://www.ncbi.nlm.nih.gov/pubmed/31185950 http://dx.doi.org/10.1186/s12885-019-5760-8

Ejemplares similares

Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma
por: Rizell, Magnus, et al.
Publicado: (2019)

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial
por: Olofsson, Roger, et al.
Publicado: (2014)

Radiopaque Fiducials Guiding Laparoscopic Resection of Liver Tumors
por: Falkenberg, Mårten, et al.
Publicado: (2021)

Erratum to: Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial
por: Olofsson Bagge, Roger, et al.
Publicado: (2015)

Combination of biomarkers for the detection of hepatocellular carcinoma
por: Sternby Eilard, Malin, et al.
Publicado: (2020)

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)
por: Olofsson Bagge, Roger, et al.
Publicado: (2023)

Treatment patterns and survival in patients with hepatocellular carcinoma in the Swedish national registry SweLiv
por: Henriksson, M., et al.
Publicado: (2019)

Targeting population groups with heavier burden of hepatocellular carcinoma incidence: A nationwide descriptive epidemiological study in Sweden
por: Vaz, Juan, et al.
Publicado: (2022)

Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection
por: Rizell, Magnus, et al.
Publicado: (2020)

Risk Factors for Postoperative Complications Following Resection of Colorectal Liver Metastases and the Impact on Long-Term Survival: A Population-Based National Cohort Study
por: Scherman, Peter, et al.
Publicado: (2023)

The Impact of Changed Strategies for Patients with Cholangiocarcinoma in This Millenium
por: Lindnér, Per, et al.
Publicado: (2015)

Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Kim, Bo Hyun, et al.
Publicado: (2018)

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2021)

Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation
por: Minoux, Kate, et al.
Publicado: (2022)

Influence of primary tumour and patient factors on survival in patients undergoing curative resection and treatment for liver metastases from colorectal cancer
por: Scherman, P., et al.
Publicado: (2019)

Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma
por: Shetty, Kirti, et al.
Publicado: (2014)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence
por: Sinakos, Emmanouil, et al.
Publicado: (2011)

Downstaging of Hepatocellular Carcinoma Prior to Liver Transplant: Is There a Role for Adjuvant Sorafenib in Locoregional Therapy?
por: Vagefi, Parsia A., et al.
Publicado: (2010)

Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma
por: Yoo, Eun Jin, et al.
Publicado: (2013)

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
por: Barbier, L., et al.
Publicado: (2011)

Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation
por: Zhang, Xia, et al.
Publicado: (2023)

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
por: Ek, Frida, et al.
Publicado: (2022)

Hepatocellular carcinoma progression during bridging before liver transplantation
por: Renner, P, et al.
Publicado: (2021)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era
por: Kim, Nae Yu, et al.
Publicado: (2010)

Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study
por: Teng, Chieh-Lin, et al.
Publicado: (2012)

Absence of antitumor effects of metformin in sorafenib-treated patients with hepatocellular carcinoma recurrence after hepatic resection and liver transplantation
por: Chung, Yong-Kyu, et al.
Publicado: (2018)

Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria
por: Cho, Yuri, et al.
Publicado: (2017)

Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients
por: Johansson, Junko, et al.
Publicado: (2018)

FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity
por: Ahmed, Dilruba, et al.
Publicado: (2015)

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
por: Saif, Muhammad W., et al.
Publicado: (2011)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Evolving role of Sorafenib in the management of hepatocellular carcinoma
por: Ziogas, Ioannis A, et al.
Publicado: (2017)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib(® )versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]
por: Hoffmann, K, et al.
Publicado: (2008)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_p5a0hc25t3jqvhkpi75k6tml0u